

FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
11502/25:1 US

APPLICATION NO.
10/624,711

INFORMATION DISCLOSURE CITATION

(Uses several sheets if necessary)

APPLICANT - Duane D. Blatter et al.

TITLE: APPARATUS AND METHODS FOR OCCLUSION OF AN
ACCESS TUBE ANASTOMOSIS TO AN ANATOMICAL
VESSEL

FILING DATE:
07/21/03

EXAMINER:
(Not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
21	1	6,401,721	06/11/02	Maginot			11/08/99
	2	6,319,226	11/20/01	Sherry			09/20/99
	3	6,293,965	09/25/01	Berg et al.			03/30/00
	4	6,280,460	08/28/01	Bolduc et al.			02/13/98
	5	6,264,633	07/24/01	Knorig			07/09/98
	6	6,261,257	07/17/01	Uffacker et al.			05/24/99
	7	6,254,563	07/03/01	Macoviak et al.			03/20/00
	8	6,248,117	06/19/01	Blatter			04/16/99
	9	6,210,365	04/03/01	Afzal			08/14/98
	10	6,200,257	03/13/01	Winkler			03/24/99
	11	6,171,319	01/09/01	Nobles et al.			04/27/99
	12	6,113,612	09/05/00	Swanson et al.			11/06/98
	13	6,102,884	08/15/00	Squitieri			04/07/97
	14	6,086,553	07/11/00	Akbik			07/01/99
	15	6,068,637	05/30/00	Popov et al.			08/29/96
	16	6,042,569	03/28/00	Finch, Jr. et al.			01/20/98
	17	6,030,392	02/29/00	Dakov			05/19/97
	18	6,007,576	12/28/99	McClellan			02/06/98
21	19	5,976,178	11/02/99	Goldsteen et al.			11/07/96

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	20	5,961,536	10/05/99	Mickley et al.			10/14/97
	21	5,954,706	09/21/99	Sahatjian			06/07/95
	22	5,925,060	07/20/99	Forber			03/13/98
	23	5,893,369	04/13/99	LeMole			02/24/97
	24	5,868,770	02/09/99	Rygaard			05/28/97
	25	5,843,027	12/01/98	Stone et al.			12/04/96
	26	5,830,228	11/03/98	Knapp et al.			05/29/96
	27	5,830,222	11/03/98	Makower			10/11/96
	28	5,817,113	10/06/98	Gifford, III et al.			01/23/97
	29	5,797,934	08/25/98	Rygaard			06/29/95
	30	5,797,879	08/25/98	DeCampi			08/26/96
	31	5,795,325	08/18/98	Valley et al.			12/11/95
	32	5,792,095	08/11/98	Kissinger et al.			07/01/96
	33	5,779,731	07/14/98	Leavitt			12/20/96
	34	5,766,158	06/16/98	Opolski			05/31/96
	35	5,755,775	05/26/98	Trerotola et al.			09/03/96
	36	5,702,412	12/30/97	Popov et al.			10/03/95
	37	5,695,504	12/09/97	Gifford, III et al.			02/24/95
	38	5,693,088	12/02/97	Lazarus			06/07/95
	39	5,662,700	09/02/97	Lazarus			11/18/94
	40	5,662,580	09/02/97	Bradshaw et al.			02/10/95
	41	5,634,936	06/03/97	Linden et al.			02/06/95
	42	5,620,649	04/15/97	Trotta			10/11/95
	43	5,617,878	04/08/97	Taheri			05/31/96

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	44	5,616,114	04/01/97	Thornton et al.			12/08/94
	45	5,613,979	03/25/97	Trotta et al.			11/01/93
	46	5,478,320	12/26/95	Trotta			01/31/94
	47	5,458,568	10/17/95	Racchini et al.			09/17/93
	48	5,456,712	10/10/95	Maginot			10/18/93
	49	5,443,497	08/22/95	Venbrux			11/22/93
	50	5,417,657	05/23/95	Hauer			10/06/93
	51	5,411,475	05/02/95	Atala et al.			04/28/93
	52	5,304,220	04/19/94	Maginot			05/03/93
	53	5,290,306	03/01/94	Trotta et al.			11/29/89
	54	5,102,402	04/07/92	Dror et al.			01/04/91
	55	5,092,841	03/03/92	Spears			05/17/90
	56	4,623,348	11/18/86	Feit			08/13/84
	57	4,846,186	07/11/89	Box et al.			01/12/88
	58	4,819,637	04/11/89	Dormandy, Jr., et al.			09/01/87
	59	4,655,771	04/07/87	Wallsten			04/11/83
	60	4,370,983	02/01/83	Lichtenstein			04/30/79
	61	4,318,401	03/09/82	Zimmerman			04/24/80
	62	4,301,797	11/24/81	Pollack			11/22/78
	63	4,122,858	10/31/78	Schiff			03/23/77
	64	3,991,756	11/16/76	Snyder			08/18/75
	65	3,826,257	06/30/74	Buselmeier			07/14/72
	66	3,395,710	08/06/68	R.A. Stratton et al.			06/14/65
	67	3,392,722	07/16/68	R. L. Jorgensen			07/29/65

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PATENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	Translation	
						YES	NO
69	WO 98/19629	05/14/98	PCT/US97/19946	A61F	2/06	/	/
	WO 98/19634	05/14/98	PCT/US97/20244	A61F	2/06	/	/
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER DOCUMENTS (Including Autho, Title, Date, Pertinent Pages, Etc.

70	Lycos, Your Personal Internet Guide, APHERESIS, located at http://infoplease.lycos.com/ipd/A0321273.html , 1 pg., printed 5/22/02
71	Clark Biocompatible Hemoperfusion System and Block Cutter, <i>Some Other Products from Clark Research, Clark® Biocompatible Hemoperfusion</i> , located at http://www.clarkrd.com/crd_other2.htm , 2pgs., printed 12/17/99.
72	HGSA Medicare Policy S-107: Hemoperfusion, <i>Medicare Medical Policy Bulletin, Freedom of Information</i> , located at http://www.hgsa.com/professionals/policy/s107.html , 1 pg., printed 5/22/02.
73	Xact Medicare Services, Xact Medicare Policy S-53: Hemofiltration (Diafiltration) <i>Medicare Medical Policy Bulletin, Freedom of Information</i> , located at http://www.xact.org/policy/s107.html , 1 pg., printed 12/17/99.
74	Facts about Plasmapheresis, <i>Plasmapheresis and Autoimmune Disease</i> , MDA Publications, located at http://www.mdausa.org/publications/fa-plasmaph.html , 4 pgs., printed 5/22/02.
75	Publications, <i>Hemodialysis</i> , located at http://www.kidney.ca/hem-e.htm , 4 pgs., printed 5/22/02.
76	Tennessee Kidney Clinics and Affiliates, <i>What is Hemodialysis?</i> located at http://www.dialysisclinics.com/hemo.htm , 1 pg., printed 5/22/02.
77	<i>Good Nutrition & Hemodialysis</i> , located at http://www.nyu.edu/classes/computrfood/Cecilia%20Fong/index.html , 1 pg., printed 5/22/02.
78	Mulzer, S.R. and Brash, J.L., <i>Identification of Plasma Proteins Adsorbed to Hemodialyzers During Clinical Use</i> , Journal of Biomedical Materials Research, Vol. 23, 1483-1504 (1989)
79	Ljungberg, B., et al., <i>Effective Anticoagulation by a Low Molecular Weight Heparin (Fragmin®) in Hemodialysis with a Highly Permeable Polysulfone Membrane</i> , Clinical Nephrology, Vol. 38, No. 2-1992 (97-100)
80	Jen Ming Yang, et al., <i>Preparation of Heparin Containing SBS-g-VP Copolymer Membrane for Biomaterial Usage</i> , Journal of Membrane Science 138 (1998) 19-27
EXAMINER	
DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CUSTOMER NO. 32642